PE20210136A1 - Formulacion farmaceutica de odevixibat - Google Patents
Formulacion farmaceutica de odevixibatInfo
- Publication number
- PE20210136A1 PE20210136A1 PE2020002088A PE2020002088A PE20210136A1 PE 20210136 A1 PE20210136 A1 PE 20210136A1 PE 2020002088 A PE2020002088 A PE 2020002088A PE 2020002088 A PE2020002088 A PE 2020002088A PE 20210136 A1 PE20210136 A1 PE 20210136A1
- Authority
- PE
- Peru
- Prior art keywords
- odevixibat
- particle
- core
- liver diseases
- coating layer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Liquid Crystal Substances (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1850762 | 2018-06-20 | ||
| SE1850761 | 2018-06-20 | ||
| PCT/SE2019/050603 WO2019245449A1 (en) | 2018-06-20 | 2019-06-20 | Pharmaceutical formulation of odevixibat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210136A1 true PE20210136A1 (es) | 2021-01-21 |
Family
ID=67138007
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020002088A PE20210136A1 (es) | 2018-06-20 | 2019-06-20 | Formulacion farmaceutica de odevixibat |
| PE2020002089A PE20210182A1 (es) | 2018-06-20 | 2019-06-20 | Modificaciones de cristales de odexibat |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020002089A PE20210182A1 (es) | 2018-06-20 | 2019-06-20 | Modificaciones de cristales de odexibat |
Country Status (34)
| Country | Link |
|---|---|
| US (5) | US11802115B2 (https=) |
| EP (2) | EP3810581B1 (https=) |
| JP (2) | JP7504032B2 (https=) |
| KR (3) | KR20210024033A (https=) |
| CN (2) | CN112312893A (https=) |
| AU (2) | AU2019290338B2 (https=) |
| BR (2) | BR112020024461A2 (https=) |
| CA (2) | CA3100691A1 (https=) |
| CL (2) | CL2020003296A1 (https=) |
| CO (2) | CO2020015772A2 (https=) |
| CR (2) | CR20210027A (https=) |
| DK (1) | DK3810581T3 (https=) |
| EC (2) | ECSP21000999A (https=) |
| ES (1) | ES3011850T3 (https=) |
| FI (1) | FI3810581T3 (https=) |
| HR (1) | HRP20250427T1 (https=) |
| HU (1) | HUE070725T2 (https=) |
| IL (2) | IL279464B2 (https=) |
| JO (2) | JOP20200299A1 (https=) |
| MX (2) | MX2020013774A (https=) |
| MY (2) | MY209425A (https=) |
| NI (2) | NI202000104A (https=) |
| PE (2) | PE20210136A1 (https=) |
| PH (2) | PH12020552165A1 (https=) |
| PL (1) | PL3810581T3 (https=) |
| PT (1) | PT3810581T (https=) |
| RS (1) | RS66694B1 (https=) |
| SA (1) | SA520420731B1 (https=) |
| SG (2) | SG11202012170PA (https=) |
| SI (1) | SI3810581T1 (https=) |
| TW (1) | TWI823954B (https=) |
| UA (1) | UA128761C2 (https=) |
| WO (2) | WO2019245448A1 (https=) |
| ZA (1) | ZA202007541B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2687027T3 (es) | 2010-11-04 | 2018-10-23 | Albireo Ab | Inhibidores de ibat para el tratamiento de enfermedades hepáticas |
| CN106659726A (zh) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
| ES2874669T3 (es) | 2016-02-09 | 2021-11-05 | Albireo Ab | Formulación oral de colestiramina y uso de la misma |
| CN108601739B (zh) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | 考来烯胺丸剂及其制备方法 |
| WO2017138878A1 (en) | 2016-02-09 | 2017-08-17 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CN112449637B (zh) | 2018-06-05 | 2024-03-19 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| PL3810581T3 (pl) | 2018-06-20 | 2025-04-28 | Albireo Ab | Modyfikacje kryształu odewiksibatu |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| TWI835997B (zh) | 2019-02-06 | 2024-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻氮呯化合物及其用作膽酸調節劑之用途 |
| CN118852054A (zh) | 2019-02-06 | 2024-10-29 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
| JP7696898B2 (ja) | 2019-12-04 | 2025-06-23 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| EP4069247B1 (en) | 2019-12-04 | 2025-03-26 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
| IL293379B2 (en) | 2019-12-04 | 2026-04-01 | Albireo Ab | Benzothia(dia)azepine compounds and their use as bile acid modulators |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| ES2973355T3 (es) | 2019-12-04 | 2024-06-19 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| EP4188541B1 (en) | 2020-08-03 | 2024-12-25 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CA3196488A1 (en) * | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| WO2022101379A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| CN116710100A (zh) * | 2020-11-12 | 2023-09-05 | 阿尔比里奥公司 | 用于治疗进行性家族性肝内胆汁淤积(pfic)的奥德昔巴特 |
| BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| WO2022166680A1 (zh) * | 2021-06-25 | 2022-08-11 | 苏州科睿思制药有限公司 | 奥德昔巴特的晶型及其制备方法和用途 |
| CN113913436B (zh) * | 2021-11-18 | 2023-09-29 | 天津市肿瘤医院（天津医科大学肿瘤医院） | 逆转录转座基因l1-atp8b1及其作为肺鳞癌标志物的用途和治疗肺鳞癌的药物 |
| WO2023174937A1 (en) | 2022-03-16 | 2023-09-21 | Sandoz Ag | Particles comprising non-crystalline odevixibat |
| EP4511038A1 (en) * | 2022-04-22 | 2025-02-26 | Albireo AB | Subcutaneous administration of an asbt inhibitor |
| CN120379676A (zh) | 2022-11-03 | 2025-07-25 | 阿尔比里奥公司 | 治疗阿拉杰里综合征(algs) |
| WO2024121431A1 (en) | 2022-12-09 | 2024-06-13 | Albireo Ab | Cocrystals of odevixibat |
| WO2024184924A1 (en) * | 2023-03-06 | 2024-09-12 | Rk Pharma Inc | "an improved process for the preparation of odevixibat and its crystalline forms" |
| AU2024369988A1 (en) | 2023-11-03 | 2026-04-09 | Albireo Ab | Treating pfic2 with odevixibat |
Family Cites Families (196)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3539380A (en) | 1968-01-08 | 1970-11-10 | Upjohn Co | Methylcellulose and polyalkylene glycol coating of solid medicinal dosage forms |
| GB1566609A (en) | 1977-03-10 | 1980-05-08 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions containing cholestyramine and alginic acid |
| GB1573487A (en) | 1977-05-23 | 1980-08-28 | Bristol Myers Co | Bile acid binding composition |
| EP0019115B1 (de) | 1979-04-30 | 1983-01-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pankreozymin-Cholezystokinin aktive Peptide, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel |
| CA1313135C (en) | 1987-02-09 | 1993-01-26 | The Dow Chemical Company | Cholestyramine composition and process for its preparation |
| US5167965A (en) | 1987-02-09 | 1992-12-01 | The Dow Chemical Company | Palatable cholestyramine granules, tablets and methods for preparation thereof |
| US4900757A (en) | 1988-12-08 | 1990-02-13 | Merrell Dow Pharmaceuticals Inc. | Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane |
| JP2800242B2 (ja) | 1989-03-30 | 1998-09-21 | 大正製薬株式会社 | 粒剤の製造方法 |
| IL95574A (en) | 1989-09-09 | 1994-11-11 | Knoll Ag | Colestyramine preparation |
| DE3930168A1 (de) | 1989-09-09 | 1991-03-14 | Knoll Ag | Verbesserte verabreichungsform fuer colestyramin |
| GB8926639D0 (en) | 1989-11-24 | 1990-01-17 | Agricultural & Food Res | Delayed release formulations |
| JP2542122B2 (ja) * | 1990-04-18 | 1996-10-09 | 旭化成工業株式会社 | 球状核、球形顆粒およびその製造方法 |
| US5250524A (en) | 1990-12-06 | 1993-10-05 | Hoechst Aktiengesellschaft | Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals |
| EP0549967B1 (de) | 1991-12-20 | 1996-03-13 | Hoechst Aktiengesellschaft | Polymere und Oligomere von Gallensäurederivaten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JPH05186357A (ja) | 1991-12-31 | 1993-07-27 | Shigeo Ochi | 飲食物消化分解産物吸収抑制手段 |
| GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
| IT1257793B (it) | 1992-05-18 | 1996-02-13 | Composizione farmaceutica a base di acidi biliari in microgranuli a rilascio controllato | |
| WO1993024109A1 (en) | 1992-06-04 | 1993-12-09 | Smithkline Beecham Corporation | Palatable pharmaceutical compositions |
| DK0573848T3 (da) | 1992-06-12 | 1998-08-10 | Hoechst Ag | Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler |
| US5350584A (en) | 1992-06-26 | 1994-09-27 | Merck & Co., Inc. | Spheronization process using charged resins |
| JP3349535B2 (ja) * | 1993-01-12 | 2002-11-25 | フロイント産業株式会社 | 球形顆粒の製造方法 |
| ZA941003B (en) | 1993-02-15 | 1995-08-14 | Wellcome Found | Hypolipidaemic compounds |
| IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| DE69425453T2 (de) | 1993-04-23 | 2001-04-12 | Novartis Ag, Basel | Wirkstoffabgabevorrichtung mit gesteuerter Freigabe |
| TW289020B (https=) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
| EP0624593A3 (de) | 1993-05-08 | 1995-06-07 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel. |
| TW289757B (https=) | 1993-05-08 | 1996-11-01 | Hoechst Ag | |
| TW289021B (https=) | 1993-05-08 | 1996-10-21 | Hoechst Ag | |
| ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
| US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US5994391A (en) | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| CN1084741C (zh) | 1994-09-13 | 2002-05-15 | 孟山都公司 | 具有回肠胆汁酸转运和牛磺胆酸盐摄入抑制剂作用的新的苯并硫杂䓬 |
| GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
| US5811388A (en) | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
| AU724620B2 (en) | 1996-01-16 | 2000-09-28 | Sokol, Ronald J Dr. | Use of antioxidant agents to treat cholestatic liver disease |
| DE19608592A1 (de) | 1996-03-06 | 1997-09-11 | Hoechst Ag | Antikörper zur selektiven immunologischen Bestimmung von Gallensäuren in biologischen Matrices |
| HUP9903047A3 (en) | 1996-03-11 | 2002-12-28 | G D Searle & Co Chicago | Novel benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| CA2253593C (en) | 1996-05-23 | 2008-07-08 | Novartis Ag | Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-fudca) |
| AU3940897A (en) | 1996-07-24 | 1998-02-10 | Zumtobel Staff Gmbh | Adapter for a retaining means used to secure a built-in lamp in a mounting hole,or retaining means or built-in lamp provided with such an adapter |
| DE19633268A1 (de) | 1996-08-19 | 1998-02-26 | Hoechst Ag | Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung |
| GB9704208D0 (en) | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
| PL336415A1 (en) | 1997-03-11 | 2000-06-19 | Searle & Co | Combined therapy employing ileic bile acid transport inhibiting benzothiepins as well as a hmg co-enzyme reductase inhibitors |
| DK0864582T3 (da) | 1997-03-14 | 2003-09-29 | Aventis Pharma Gmbh | Hypolidemiske 1,4-benzothiazepin-1,1-dioxider |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| WO1998055107A1 (en) | 1997-06-06 | 1998-12-10 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| AU7552198A (en) | 1997-06-11 | 1998-12-30 | Sankyo Company Limited | Benzylamine derivatives |
| AUPO763197A0 (en) | 1997-06-30 | 1997-07-24 | Sigma Pharmaceuticals Pty Ltd | Health supplement |
| US5900233A (en) | 1997-10-16 | 1999-05-04 | Day; Charles E. | Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome |
| US20030153541A1 (en) | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
| ATE234829T1 (de) | 1997-12-19 | 2003-04-15 | Searle & Co | Verfahren zu herstellung von enantiomerisch- anreicherte tetrahydrobenzothiepin oxyden |
| GB9800428D0 (en) | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
| US6346527B1 (en) | 1998-04-24 | 2002-02-12 | Fujisawa Pharmaceutical Co., Ltd. | Guanidine derivatives |
| DE19825804C2 (de) | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| EP1103552A4 (en) | 1998-08-07 | 2003-01-15 | Takeda Chemical Industries Ltd | BENZOTHIEPINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| PT1140190E (pt) | 1998-12-23 | 2003-02-28 | Searle Llc | Combinacoes de inibidores do transporte ileal dos acidos biliares e agentes sequestrantes dos acidos biliares usadas para problemas cardiovasculares |
| KR20020002367A (ko) | 1998-12-23 | 2002-01-09 | 윌리암스 로저 에이 | 심혈관 징후를 위한 조합물 |
| JP2002533415A (ja) | 1998-12-23 | 2002-10-08 | ジー．ディー．サール エルエルシー | 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびニコチン酸誘導体の組み合わせ |
| JP2002533412A (ja) | 1998-12-23 | 2002-10-08 | ジー．ディー．サール エルエルシー | 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびコレステリルエステル転送タンパク質阻害剤の組み合わせ |
| WO2000038727A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
| JP2002536440A (ja) | 1999-02-12 | 2002-10-29 | ジー．ディー．サール エルエルシー | 回腸胆汁酸輸送およびタウロコール酸塩取り込みの阻害剤としての活性を有する新規１，２−ベンゾチアゼピン |
| DE19915420A1 (de) | 1999-04-06 | 2000-10-12 | Basf Ag | Stabilisierte Polyvinylpyrrolidon-Zubereitungen |
| DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
| SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
| US6287609B1 (en) | 1999-06-09 | 2001-09-11 | Wisconsin Alumni Research Foundation | Unfermented gel fraction from psyllium seed husks |
| US20020054903A1 (en) | 1999-10-19 | 2002-05-09 | Joseph Tyler | Direct compression polymer tablet core |
| AU1302301A (en) | 1999-11-08 | 2001-06-06 | Sankyo Company Limited | Nitrogenous heterocycle derivatives |
| GB9927088D0 (en) | 1999-11-17 | 2000-01-12 | Secr Defence | Use of poly(diallylamine) polymers |
| JP2003523336A (ja) | 2000-02-18 | 2003-08-05 | メルク エンド カムパニー インコーポレーテッド | 糖尿病及び脂質障害のためのアリールオキシ酢酸 |
| SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| US6586434B2 (en) | 2000-03-10 | 2003-07-01 | G.D. Searle, Llc | Method for the preparation of tetrahydrobenzothiepines |
| WO2001068096A2 (en) | 2000-03-10 | 2001-09-20 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
| TWI241195B (en) | 2000-04-10 | 2005-10-11 | Shionogi & Co | Preventive agent for bile acidic diarrhea |
| US6638498B2 (en) | 2000-06-30 | 2003-10-28 | Semorex Inc. | Molecularly imprinted polymers for the treatment and diagnosis of medical conditions |
| US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| RU2241462C2 (ru) | 2000-07-28 | 2004-12-10 | Ф. Хоффманн-Ля Рош Аг | Новая фармацевтическая композиция |
| FR2812886B1 (fr) | 2000-08-08 | 2002-11-08 | Assist Publ Hopitaux De Paris | Depistage d'un nouveau syndrome hepatique et ses applications |
| SE0003766D0 (sv) | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| WO2002053548A1 (fr) | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Derives de la benzothiazepine |
| US6506921B1 (en) | 2001-06-29 | 2003-01-14 | Virginia Tech Intellectual Properties, Inc. | Amine compounds and curable compositions derived therefrom |
| US20040077625A1 (en) | 2001-07-25 | 2004-04-22 | Tremont Samuel J. | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake |
| US20040038862A1 (en) | 2001-07-30 | 2004-02-26 | Goodwin Bryan James | Identification of new therapeutic targets for modulating bile acid synthesis |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| AU2002329387B2 (en) | 2001-09-08 | 2007-06-07 | Albireo Ab | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia |
| AU2002332638A1 (en) | 2001-09-12 | 2003-03-24 | G.D. Searle Llc | Method for the preparation of crystalline tetrahydrobenzothiepines |
| BR0213501A (pt) | 2001-11-02 | 2004-08-24 | Searle Llc | Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato |
| TW200300349A (en) | 2001-11-19 | 2003-06-01 | Sankyo Co | A 4-oxoqinoline derivative |
| GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| GB0314079D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| SE0104334D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| WO2003059378A2 (en) | 2001-12-29 | 2003-07-24 | Novo Nordisk A/S | Combined use of a glp-1 compound and another drug for treating dyslipidemia |
| GB0201850D0 (en) | 2002-01-26 | 2002-03-13 | Astrazeneca Ab | Therapeutic treatment |
| US20040014806A1 (en) | 2002-03-08 | 2004-01-22 | Pharmacia Corporation | Methods and compositions for lowering levels of blood lipids |
| EP1490029A4 (en) | 2002-03-22 | 2006-02-22 | Ranbaxy Lab Ltd | DRUG DELIVERY SYSTEM WITH CONTROLLED RELEASE OF PRAVASTATIN |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| GB0216321D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
| CN100494185C (zh) | 2002-08-28 | 2009-06-03 | 旭化成制药株式会社 | 新型季铵化合物 |
| US7312208B2 (en) | 2002-08-28 | 2007-12-25 | Asahi Kasei Pharma Corporation | Quaternary ammonium compounds |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| WO2004076657A2 (en) | 2003-02-28 | 2004-09-10 | Mcgill University | Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides |
| US20060210633A1 (en) | 2003-04-03 | 2006-09-21 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
| AU2008202120B2 (en) * | 2003-04-05 | 2009-12-17 | Albireo Ab | Use of an IBAT inhibitor for the treatment of prophylaxis of constipation |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| WO2005036971A1 (en) | 2003-10-16 | 2005-04-28 | Techcom Group, Llc | Reduced digestible carbohydrate food having reduced blood glucose response |
| KR20070026392A (ko) | 2004-02-27 | 2007-03-08 | 아사히 가세이 파마 가부시키가이샤 | 신규 벤조티아제핀 및 벤조티에핀 화합물 |
| US20050197376A1 (en) | 2004-03-02 | 2005-09-08 | Fujisawa Pharmaceutical Co. Ltd. | Concomitant drugs |
| EP1593671A1 (en) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV inhibitors |
| US20050215882A1 (en) | 2004-03-23 | 2005-09-29 | The Regents Of The University Of Michigan | Noninvasive method to determine fat content of tissues using MRI |
| TWI415635B (zh) | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
| US20050287178A1 (en) | 2004-06-23 | 2005-12-29 | Steed Barrie L | Diagnosis and treatment of heavy gallbladder densities |
| JP4896480B2 (ja) | 2004-10-01 | 2012-03-14 | 第一三共ヘルスケア株式会社 | 陰イオン交換樹脂の粒子状組成物 |
| US9149439B2 (en) | 2005-03-21 | 2015-10-06 | Sandoz Ag | Multi-particulate, modified-release composition |
| US20090131395A1 (en) | 2005-05-05 | 2009-05-21 | Microbia, Inc. | Biphenylazetidinone cholesterol absorption inhibitors |
| US20080193543A1 (en) | 2005-05-17 | 2008-08-14 | Brown University Research Foundation | Drug Delivery Formulations For Targeted Delivery |
| US20070237818A1 (en) | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
| DE102005033099A1 (de) | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
| DE102005033100B3 (de) | 2005-07-15 | 2007-01-25 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung |
| EP1928499B1 (en) | 2005-09-20 | 2011-06-29 | Novartis AG | Use of a dpp-iv inhibitor to reduce hypoglycemic events |
| WO2007120592A1 (en) | 2006-04-10 | 2007-10-25 | Merck & Co., Inc. | Cgrp antagonist salt |
| GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
| US8048413B2 (en) | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
| DE102006053635B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| DE102006053636B4 (de) | 2006-11-14 | 2008-09-18 | Sanofi-Aventis Deutschland Gmbh | Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung |
| DE502007006208D1 (de) | 2006-11-14 | 2011-02-17 | Sanofi Aventis Deutschland | Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102006053637B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| AU2008209566C1 (en) | 2007-01-19 | 2013-02-14 | Intercept Pharmaceuticals, Inc. | 23-substituted bile acids as TGR5 modulators and methods of use thereof |
| ATE476176T1 (de) | 2007-03-02 | 2010-08-15 | Farnam Co Inc | Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung |
| DK2200588T3 (da) | 2007-09-25 | 2019-07-01 | Solubest Ltd | Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf |
| US9295677B2 (en) | 2008-02-26 | 2016-03-29 | Qing Bile Therapeutics Inc. | Polyhydroxylated bile acids for treatment of biliary disorders |
| BRPI0918499A2 (pt) | 2008-09-02 | 2015-12-01 | Usv Ltd | polímeros reticulados |
| WO2010062861A2 (en) | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| WO2011075539A2 (en) | 2009-12-18 | 2011-06-23 | Satiogen Pharmaceuticals, Inc. | Treatment of obesity or diabetes with bile acid sequestrants |
| KR101820374B1 (ko) | 2010-02-23 | 2018-01-19 | 다 볼떼라 | 장 내 흡착제의 경구 전달을 위한 제형 |
| JO3131B1 (ar) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
| ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
| ES2687027T3 (es) | 2010-11-04 | 2018-10-23 | Albireo Ab | Inhibidores de ibat para el tratamiento de enfermedades hepáticas |
| WO2012064268A1 (en) | 2010-11-08 | 2012-05-18 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
| US20120114588A1 (en) | 2010-11-08 | 2012-05-10 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
| DK2637646T3 (en) * | 2010-11-08 | 2016-08-29 | Albireo Ab | PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder |
| US20130108573A1 (en) * | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease |
| AU2012328526B2 (en) | 2011-10-28 | 2017-05-25 | Shire Human Genetic Therapies, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| JP5663699B2 (ja) | 2012-05-07 | 2015-02-04 | キッセイ薬品工業株式会社 | ピラゾール誘導体及びその医薬用途 |
| CA2907230A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| KR20160119863A (ko) | 2014-02-27 | 2016-10-14 | 뉴서트 사이언시스, 인크. | 간 지방증의 감소 또는 예방을 위한 조성물 및 방법 |
| EP3154523B1 (en) | 2014-06-16 | 2018-11-21 | Valpharma International S.P.A. | Formulation for oral administration containing mesalazine |
| CA2952405A1 (en) * | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for stabilizing the same |
| CN106659726A (zh) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
| KR101674806B1 (ko) | 2014-10-20 | 2016-11-10 | 씨제이헬스케어 주식회사 | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| US9684018B2 (en) | 2014-11-19 | 2017-06-20 | Texas Instruments Incorporated | Current sense circuit that operates over a wide range of currents |
| KR20160061492A (ko) | 2014-11-21 | 2016-06-01 | 삼성디스플레이 주식회사 | 휴대용 먼지 센서 및 이를 이용한 휴대전화 |
| CN105985254B (zh) | 2015-02-17 | 2018-03-16 | 上海中科绿碳化工科技有限公司 | 一种制备甲酰胺类化合物的方法 |
| ES2874669T3 (es) | 2016-02-09 | 2021-11-05 | Albireo Ab | Formulación oral de colestiramina y uso de la misma |
| CN108601739B (zh) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | 考来烯胺丸剂及其制备方法 |
| WO2017138878A1 (en) | 2016-02-09 | 2017-08-17 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11350844B2 (en) | 2016-11-23 | 2022-06-07 | Mayo Foundation For Medical Education And Research | System and method for generating nonalcoholic fatty liver disease activity score (NAS) using magnetic resonance elastography |
| KR101844184B1 (ko) | 2017-07-21 | 2018-04-02 | 씨제이헬스케어 주식회사 | 아미노알킬벤조티아제핀 유도체의 용도 |
| EP3664782B1 (en) | 2017-08-09 | 2025-01-29 | Albireo AB | Cholestyramine pellets, oral cholestyramine formulations and medical use thereof |
| CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
| CA3091338A1 (en) | 2018-03-09 | 2019-09-12 | Elobix Ab | Process for the preparation of elobixibat |
| CN112449637B (zh) | 2018-06-05 | 2024-03-19 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| PL3810581T3 (pl) | 2018-06-20 | 2025-04-28 | Albireo Ab | Modyfikacje kryształu odewiksibatu |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US20200046758A1 (en) | 2018-08-09 | 2020-02-13 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US20200046757A1 (en) | 2018-08-09 | 2020-02-13 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations, and uses thereof |
| AU2019350487A1 (en) | 2018-09-27 | 2021-05-13 | Albireo Energy, Llc | System, apparatus and hybrid VAV device with multiple heating coils |
| CN118852054A (zh) | 2019-02-06 | 2024-10-29 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
| TWI835997B (zh) | 2019-02-06 | 2024-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻氮呯化合物及其用作膽酸調節劑之用途 |
| EP3923943B1 (en) | 2019-02-12 | 2024-07-31 | Mirum Pharmaceuticals, Inc. | Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency |
| US20220105218A1 (en) | 2019-02-15 | 2022-04-07 | The Board Of Trustees Of The Leland Standford Junior University | Methods and systems for reducing a pathogen population |
| ES2973355T3 (es) | 2019-12-04 | 2024-06-19 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| EP4069247B1 (en) | 2019-12-04 | 2025-03-26 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
| WO2021110887A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| IL293379B2 (en) | 2019-12-04 | 2026-04-01 | Albireo Ab | Benzothia(dia)azepine compounds and their use as bile acid modulators |
| JP7696898B2 (ja) | 2019-12-04 | 2025-06-23 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| WO2021110884A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| AR120676A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
| TWI877263B (zh) | 2019-12-04 | 2025-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP4188541B1 (en) | 2020-08-03 | 2024-12-25 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CA3196488A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| EP4511038A1 (en) | 2022-04-22 | 2025-02-26 | Albireo AB | Subcutaneous administration of an asbt inhibitor |
| KR20250022025A (ko) | 2022-06-09 | 2025-02-14 | 알비레오 에이비 | 간염 치료 |
| CN119487013A (zh) | 2022-07-05 | 2025-02-18 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
-
2019
- 2019-06-20 PL PL19734937.6T patent/PL3810581T3/pl unknown
- 2019-06-20 CA CA3100691A patent/CA3100691A1/en active Pending
- 2019-06-20 KR KR1020217001712A patent/KR20210024033A/ko not_active Ceased
- 2019-06-20 TW TW108121584A patent/TWI823954B/zh active
- 2019-06-20 CN CN201980041077.4A patent/CN112312893A/zh active Pending
- 2019-06-20 HR HRP20250427TT patent/HRP20250427T1/hr unknown
- 2019-06-20 JO JOP/2020/0299A patent/JOP20200299A1/ar unknown
- 2019-06-20 WO PCT/SE2019/050602 patent/WO2019245448A1/en not_active Ceased
- 2019-06-20 CR CR20210027A patent/CR20210027A/es unknown
- 2019-06-20 SI SI201930919T patent/SI3810581T1/sl unknown
- 2019-06-20 MX MX2020013774A patent/MX2020013774A/es unknown
- 2019-06-20 SG SG11202012170PA patent/SG11202012170PA/en unknown
- 2019-06-20 BR BR112020024461-9A patent/BR112020024461A2/pt unknown
- 2019-06-20 HU HUE19734937A patent/HUE070725T2/hu unknown
- 2019-06-20 EP EP19734937.6A patent/EP3810581B1/en active Active
- 2019-06-20 FI FIEP19734937.6T patent/FI3810581T3/fi active
- 2019-06-20 SG SG11202012151XA patent/SG11202012151XA/en unknown
- 2019-06-20 PE PE2020002088A patent/PE20210136A1/es unknown
- 2019-06-20 CA CA3100687A patent/CA3100687A1/en active Pending
- 2019-06-20 PT PT197349376T patent/PT3810581T/pt unknown
- 2019-06-20 JP JP2020570784A patent/JP7504032B2/ja active Active
- 2019-06-20 IL IL279464A patent/IL279464B2/en unknown
- 2019-06-20 AU AU2019290338A patent/AU2019290338B2/en active Active
- 2019-06-20 AU AU2019290337A patent/AU2019290337B2/en active Active
- 2019-06-20 CR CR20210026A patent/CR20210026A/es unknown
- 2019-06-20 EP EP19735664.5A patent/EP3810084A1/en active Pending
- 2019-06-20 US US16/477,160 patent/US11802115B2/en active Active
- 2019-06-20 PE PE2020002089A patent/PE20210182A1/es unknown
- 2019-06-20 MY MYPI2020006589A patent/MY209425A/en unknown
- 2019-06-20 UA UAA202100179A patent/UA128761C2/uk unknown
- 2019-06-20 MX MX2020013839A patent/MX2020013839A/es unknown
- 2019-06-20 CN CN201980039118.6A patent/CN112262130B/zh active Active
- 2019-06-20 WO PCT/SE2019/050603 patent/WO2019245449A1/en not_active Ceased
- 2019-06-20 BR BR112020024479-1A patent/BR112020024479A2/pt unknown
- 2019-06-20 MY MYPI2020006412A patent/MY210563A/en unknown
- 2019-06-20 RS RS20250346A patent/RS66694B1/sr unknown
- 2019-06-20 DK DK19734937.6T patent/DK3810581T3/da active
- 2019-06-20 KR KR1020217001711A patent/KR102811961B1/ko active Active
- 2019-06-20 ES ES19734937T patent/ES3011850T3/es active Active
- 2019-06-20 KR KR1020257042275A patent/KR20260003419A/ko active Pending
- 2019-06-20 JP JP2020570778A patent/JP7448490B2/ja active Active
- 2019-06-20 IL IL279468A patent/IL279468B2/en unknown
- 2019-06-20 JO JOP/2020/0297A patent/JOP20200297A1/ar unknown
- 2019-07-10 US US16/508,036 patent/US10975046B2/en active Active
-
2020
- 2020-10-07 US US17/065,245 patent/US11365182B2/en active Active
- 2020-12-03 ZA ZA2020/07541A patent/ZA202007541B/en unknown
- 2020-12-07 SA SA520420731A patent/SA520420731B1/ar unknown
- 2020-12-14 PH PH12020552165A patent/PH12020552165A1/en unknown
- 2020-12-15 CO CONC2020/0015772A patent/CO2020015772A2/es unknown
- 2020-12-15 NI NI202000104A patent/NI202000104A/es unknown
- 2020-12-15 CO CONC2020/0015781A patent/CO2020015781A2/es unknown
- 2020-12-15 NI NI202000103A patent/NI202000103A/es unknown
- 2020-12-15 PH PH12020552168A patent/PH12020552168A1/en unknown
- 2020-12-18 CL CL2020003296A patent/CL2020003296A1/es unknown
- 2020-12-18 CL CL2020003295A patent/CL2020003295A1/es unknown
-
2021
- 2021-01-07 EC ECSENADI2021999A patent/ECSP21000999A/es unknown
- 2021-01-08 EC ECSENADI20211547A patent/ECSP21001547A/es unknown
-
2022
- 2022-05-13 US US17/744,429 patent/US12091394B2/en active Active
-
2024
- 2024-07-19 US US18/778,225 patent/US20250019354A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210136A1 (es) | Formulacion farmaceutica de odevixibat | |
| CN101674820B (zh) | 在联合治疗中应用组蛋白脱乙酰酶抑制剂并监测生物标志物的方法 | |
| ES2568260T3 (es) | Compuestos de pirimidin hidroxi amida como inhibidores de proteína desacetilasa y métodos de uso de los mismos | |
| ES2402789T3 (es) | Métodos, composicones y kits para tratar dolor y prurito | |
| JP6670841B2 (ja) | フェノール酸ｔｒｐｖ１アゴニストのプロドラッグ | |
| RU2011123371A (ru) | Кристаллические формы гидрохлорида финголимода | |
| JP7074750B2 (ja) | カルバモイルフェニルアラニノール化合物およびその使用 | |
| JP2013525318A5 (https=) | ||
| JP2018533560A5 (https=) | ||
| ES2676412T3 (es) | Inhibidores de matriptasa y usos de los mismos contra infecciones por ortomixovirus | |
| WO2022174194A1 (en) | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| US11286260B2 (en) | P38α mitogen-activated protein kinase inhibitors | |
| ES2928739T3 (es) | Inhibidores de enzimas peptidil arginina desiminasa (PAD) y usos de los mismos | |
| US20260102422A1 (en) | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| JP2012519704A (ja) | 認知増強用化合物及び組成物、製造法、並びに治療法 | |
| RS54589B1 (sr) | Novi oblici i soli dihidropirolo[1,2-c]imidazolila kao inhibitori aldosteron sintaze ili aromataze | |
| US20100311678A1 (en) | Methods and compositions for treating cancer and modulating signal transduction and metabolism pathways | |
| BRPI0517204A (pt) | sulfato de levosalbutamol cristalino (forma i), sulfato de levosalbutamol cristalino (forma ii), sulfato de levosalbutamol cristalino (forma iii), processo para preparar a forma i do sulfato de levosalbutamol cristalino, processo para preparar a forma ii do sulfato de levosalbutamol cristalino, processo para preparar a forma iii do sulfato de levosalbutamol, composição farmacêutica, composto, combinação, pó seco para inalador, processo para preparar um pó seco para inalador, processo para preparar uma composição famacêutica, processo para fabricação de uma composição farmacêutica, método para tratamento de um mamìfero, e uso de uma combinação de salbutamol | |
| JP2018500560A5 (https=) | ||
| JP2015512948A5 (https=) | ||
| CL2012001601A1 (es) | Compuestos derivados de tiazoles biciclicos, composición farmacéutica; proceso para preparar la composición farmacéutica; kit farmacéutico que los comprende; y su uso en la prevención o tratamiento de enfermedades en las cuales el efecto neuromodulador de los moduladores alostericos de mglur5 es beneficioso. | |
| JP2023503271A (ja) | （２ｒ，６ｒ）－ヒドロキシノルケタミンの塩、それらの結晶形、およびその製造方法 | |
| AU2016227080A1 (en) | Quinuclidine derivative |